Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Differential marker for diagnosis of dengue fever and dengue hemorrhagic fever

A technology for dengue hemorrhagic fever and dengue fever, applied in analytical materials, biological tests, biochemical equipment and methods, etc., can solve problems such as difficult diagnosis and complex clinical manifestations of dengue virus infection

Inactive Publication Date: 2018-09-21
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The clinical manifestations of dengue virus infection are very complex, and most of the symptoms are indistinguishable from diseases such as malaria, typhoid fever, and chikungunya fever. It is difficult to make a clear diagnosis based solely on the epidemiological data and clinical manifestations of patients, so laboratory tests are required for further diagnosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Differential marker for diagnosis of dengue fever and dengue hemorrhagic fever
  • Differential marker for diagnosis of dengue fever and dengue hemorrhagic fever
  • Differential marker for diagnosis of dengue fever and dengue hemorrhagic fever

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Example 1 Screening of differentially expressed genes in patients with dengue fever and / or dengue hemorrhagic fever and normal people

[0061] 1. Research objects:

[0062]Disease group: 5 patients with dengue fever and 5 patients with dengue hemorrhagic fever were collected, all patients were collected according to "WHO / TDR.Dengue-Guidelines for diagnosis, Treatment, prevention and control.2009; http: / / www.who.int / tdr / publications / training-guideline-publications / dengue-diagnosis-treat ment / en / index.html.Date of Access:12 / 05 / 2015.2009” to confirm the diagnosis.

[0063] Normal group: 4 healthy volunteers were selected.

[0064] There was no significant difference in age and gender between the two groups (P>0.10), and they were comparable.

[0065] All subjects were informed about this study and signed the informed consent.

[0066] 2. Extraction of total RNA from blood

[0067] (1) Fresh whole blood, erythrocyte lysate (1:1), invert and mix several times, and let s...

Embodiment 2

[0084] Example 2 Validation of differentially expressed genes in dengue fever and / or dengue hemorrhagic fever patients and normal people by reverse transcription PCR experiments

[0085] The differentially expressed gene-BRCA2 gene screened in Example 1 was selected for large sample verification.

[0086] 1. Research objects:

[0087] Disease group: 30 patients with dengue fever and 25 patients with dengue hemorrhagic fever were collected, all patients were collected according to "WHO / TDR.Dengue-Guidelines for diagnosis, Treatment, prevention and control.2009; http: / / www.who.int / tdr / publications / training-guideline-publications / dengue-diagnosis-treat ment / en / index.html.Date of Access:12 / 05 / 2015.2009” to confirm the diagnosis.

[0088] Normal group: 30 healthy volunteers were selected.

[0089] There was no significant difference in age and gender between the two groups (P>0.10), and they were comparable.

[0090] All subjects were informed about this study and signed the in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of BRCA2 gene and the expression product in preparing a diagnostic product. The diagnostic product can be used for the diagnosis of dengue fever and dengue hemorrhagic fever. By detecting the level of the BRCA2 gene and the expression product, it is possible to determine the risk of dengue fever and dengue hemorrhagic fever in the subject or the status of dengue fever and dengue hemorrhagic fever. The diagnostic product uses the peripheral blood of a subject as a detection object, and can achieve the non-invasive, rapid, sensitive and accurate diagnosticresults.

Description

technical field [0001] The invention belongs to the field of epidemiological diagnosis and prevention, and relates to a BRCA2 gene for diagnosing dengue fever and dengue hemorrhagic fever and its application. Background technique [0002] Since the Antonine plague (Shrap R, Lotka A J.A Problem in AgeDistribution[J].Philosophical Magazine, 1911,21:35-438) in the 2nd century AD, infectious diseases have been endangering human health and brought huge impacts on social stability. Impact. In recent years, the incidence of dengue infectious disease has increased rapidly and has become a world public health problem, and it is recorded as a disease in Appendix II of the newly revised International Health Regulations (2005). Dengue fever is an acute infectious disease caused by dengue virus and transmitted by Aedes mosquitoes. At first, people named it joint fever and fracture fever according to its symptoms (Monath, T.P. Dengue: The risk to developed and developing countries: Proc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883G01N33/68
CPCC12Q1/6883C12Q2600/158G01N33/6893Y02A50/30
Inventor 贾宏毅向常娟
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com